

## GP 方案双路腹腔温热灌注化疗并全身化疗治疗晚期胰腺癌临床观察

王 冰<sup>1\*</sup>,于世英<sup>1</sup>,周珞华<sup>2</sup>,于 丁<sup>3</sup>

1. 430030 武汉,华中科技大学同济医学院附属同济医院肿瘤治疗中心;2. 武汉科技大学医学院肿瘤外科;3. 湖北省肿瘤医院肿瘤内科(\* 现工作单位:323000 浙江省丽水市人民医院肿瘤内科)

### Clinical Observation on GP Combined Intravenous with Intraperitoneal Hyperthermic Perfusion Chemotherapy for Advanced Pancreatic Cancer

WANG Bing<sup>1\*</sup>, YU Shi-ying<sup>1</sup>, ZHOU Luo-hua<sup>2</sup>, YU Ding<sup>3</sup>

1. Cancer center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 2. Department of Surgical Oncology, Hospital Affiliated to Wuhan University of Science and Technology; 3. Department of Medical Oncology, Hubei Cancer Hospital (\* Present :Department of Medical Oncology, People's Hospital of Lishui, 323000)

- 摘要
- 参考文献
- 相关文章

全文: PDF (117 KB) HTML (0 KB) 输出: BibTeX | EndNote (RIS) 背景资料

**摘要** 目的 探讨晚期胰腺癌腹腔双路温热灌注化疗并全身化疗的效果。方法 选择经病理确诊的晚期胰腺癌患者26例,行腹腔单点穿刺灌注40℃的0.9%的生理盐水2500ml~3500ml+顺铂80~100mg/m<sup>2</sup>+地塞米松10mg+速尿40mg的混合液d1。腹腔给药的同时,静脉滴注林格氏液1500ml+硫代硫酸钠(STS)20~40g,12h滴完,顺铂与STS的用量比例为1:200。次日STS的剂量减半静脉滴注12h;吉西他滨1.0~1.25g/m<sup>2</sup>ivdripd1,8。3~4周为1周期,共4周期。并观察其疗效及毒副反应。结果 按WHO实体瘤近期疗效评价标准评价,26例患者均可评价,其中位生存期8个月,总有效率为38.5%,主要毒副反应为骨髓抑制。其他毒副反应较轻,一般可以耐受。结论 GP方案行双路腹腔温热灌注化疗治疗晚期胰腺癌的临床疗效较好,值得进一步探讨。

**关键词:** 胰腺癌 温热化疗 全身化疗

**Abstract:** Objective To explore the effect of combined intravenous with intraperitoneal hyperthermic perfusion chemotherapy for the advanced pancreatic cancer. Methods Twenty2six patient s with advanced pancreatic cancer diagnosed by pathology were chosen as our subjects. Every subject was treated with the following regimen , administered every 21~28 days. 2500~3500 ml normal saline of 40 °C mixed with cisplatin 80~100 mg/ m<sup>2</sup> plus dexamethasone 10 mg plus furosemide 40mg were perfused by abdomen puncture , on d1 . Followed by Ringer 1500 ml plus STS 20~40 g by iv within 12 hours. And the next day , half dose of STS by iv within 12 hours also. Simultaneously gemcitabine 1. 0~1. 25 g/ m<sup>2</sup> by iv on d1 , d8 . 21~28 days were 1 cycle , All the patient s received 4 cycles. And effect and toxicity were observed. Results Twenty-six cases could be evaluated according to Response Evaluation Criteria in Solid Tumors , the median survival time was 8 months. The total response rate was 38. 5 % , myelosuppression was the main toxicity. Non0hemotological toxicity was mild and tolerable. Conclusion The GP combined intravenous with int raperitoneal hyperthermic perfusion treatment is an effective regiment in the treatment of advanced pancreatic cancer , and we should study it further.

**Key words:** Pancreatic cancer Chemical Treatment Intrapertoneal hyperthermic perfusion

收稿日期: 2006-11-14;

通讯作者: 王 冰

引用本文:

王 冰 ,于世英,周珞华等. GP 方案双路腹腔温热灌注化疗并全身化疗治疗晚期胰腺癌临床观察[J]. 肿瘤防治研究, 2007, 34(8): 620-622.

WANG Bing ,YU Shi-ying,ZHOU Luo-hua et al. Clinical Observation on GP Combined Intravenous with Intraperitoneal Hyperthermic Perfusion Chemotherapy for Advanced Pancreatic Cancer[J]. CHINA RESEARCH ON PREVENTION AND TREATMENT, 2007, 34(8): 620-622.

#### 服务

- 把本文推荐给朋友
- 加入我的书架
- 加入引用管理器
- E-mail Alert
- RSS

#### 作者相关文章

- 王 冰
- 于世英
- 周珞华
- 于 丁

- [1] 郑浩;汤志刚. 5-Aza-dC对胰腺癌细胞系Panc-1中TFPI-2基因甲基化水平及表达的影响[J]. 肿瘤防治研究, 2012, 39(2): 150-153.
- [2] 孙建建;李胜棉;赵松;李光辉;王小玲. Survivin和Caspase-3在胰腺癌组织中的表达及与预后的关系[J]. 肿瘤防治研究, 2012, 39(1): 62-67.
- [3] 丁军利;夏钰弘;刘超英;许隽颖. M2型肿瘤相关巨噬细胞在胰腺癌中的表达及其临床意义[J]. 肿瘤防治研究, 2012, 39(1): 59-61.
- [4] 方珏敏综述;王理伟审校. 一氧化氮在胰腺癌发生发展中的作用[J]. 肿瘤防治研究, 2012, 39(1): 110-112.
- [5] 林远洪;雷小林;吴永忠;高泽莉. 靶向EGFR基因的shRNA抑制胰腺癌PANC-1细胞增殖的研究[J]. 肿瘤防治研究, 2011, 38(9): 1012-1015.
- [6] 穆晓峰;王迎选;俞立权;宁健;曹京旭;史铭;付淑云;宋薇;李韧. 血清CA19-9、CEA、CA125动态变化在判断胰腺癌同期化疗患者疗效及预后中的应用[J]. 肿瘤防治研究, 2011, 38(9): 1038-1041.
- [7] 李泉旺;何秀兰;孙韬;肖俐;姜敏;刘传波;胡凯文. 靶动脉灌注化疗联合华蟾素泵入治疗晚期胰头癌30例[J]. 肿瘤防治研究, 2011, 38(4): 469-470.
- [8] 杨俭;李胜棉;刘世正;王晓辰;刘晓燕;刘江惠;宋淑霞;王俊霞. Smac过表达对人胰腺癌MiaPaCa-2细胞的化疗增敏作用[J]. 肿瘤防治研究, 2011, 38(3): 341-343.
- [9] 崔海宁;余壮明;于飞;顾冠宏. rAAV-Slug-siRNA载体的构建及其抗胰腺癌的实验[J]. 肿瘤防治研究, 2011, 38(3): 265-269.
- [10] 王磊;沈泽天;朱锡旭. 健择联合电子线照射对人胰腺癌裸鼠移植瘤凋亡的影响[J]. 肿瘤防治研究, 2011, 38(2): 144-147.
- [11] 齐晓光;王立夫;孙 罡;林晓琳. 肿瘤标志物在胰腺占位中的鉴别诊断价值[J]. 肿瘤防治研究, 2010, 37(5): 592-593.
- [12] 谢启启;赵秋;柯晓煜;范学科;刘志清. 胰腺癌组织存活素和极光B表达的相关性[J]. 肿瘤防治研究, 2010, 37(2): 185-188.
- [13] 唐瑞峰;齐 帅;苑建磊;孙 超;田贵金;李智峰;张志明. 细胞因子IL-2和IL-6对胰腺癌细胞表达VEGF-D的调节[J]. 肿瘤防治研究, 2009, 36(8): 651-654.
- [14] 刘 琳;李任飞;申宝忠. 动脉置管热灌注化疗治疗胰腺癌的疗效观察[J]. 肿瘤防治研究, 2009, 36(7): 611-614.
- [15] 马向涛;余力伟;付静. 消化道恶性肿瘤皮肤转移[J]. 肿瘤防治研究, 2009, 36(6): 518-519.